Table 3.

Ongoing trials with nivolumab in monotherapy.

Study/ClinicalTrials.gov identifier status	Population	Phase/primary endpoint	Regimens
CA209-374/NCT02596035: recruiting	Untreated and pretreated adv/met ccRCC and nccRCC	IIIB−IV/safety	ccRCC cohort: nivo 240 mg IV q2w nccRCC cohort: nivo 240 mg IV q2w Brain metastases cohort: nivo 240 mg IV q2w
NCT02575222: recruiting	Nonmet stage II−IV ccRCC eligible for nephrectomy	I/safety and tolerability	Three doses of nivo 3 mg/kg q2w prior to nephrectomy
ADAPTeR/NCT02446860: recruiting	Met RCC eligible for nephrectomy	II/safety: biomarker analysis	Biopsy of primary tumor, followed by 8 weeks of nivo, followed by nephrectomy, then postoperatively until patient is no longer deriving clinical benefit
NCT02595918: not yet recruiting	High-risk nonmet kidney cancer	I/safety-biomarker analysis	Three doses of nivo and complete surgery

Adv, advanced; met, metastatic; RCC, renal cell carcinoma; ccRCC, clear-cell renal cell carcinoma; nccRCC, nonclear-cell renal cell carcinoma; nivo, nivolumab; q2w, every 2 weeks.